AOC 1001
Avidity Biosciences
['in-person']
following our presentation at #aanam today, members from our management team, along with dr. nicholas johnson, vcu, will present topline data from our phase 1/2 marina clinical trial in dm1 at an investor &amp; analyst event at 5:30pm et in boston. register: 
Avidity Biosciences is pioneering a new class of oligonucleotide-based therapies to address the unmet needs of the rare disease community.